Retatrutide.
B💡 Explain this simply
Retatrutide is an investigational compound in the glp-1 & incretin receptor agonists.
It draws interest for glp-1 & incretin receptor agonists.
B-tier evidence: some human evidence exists but isn't definitive.
General anti-aging / longevity; Human injury recovery; Muscle growth or fat loss claims.
Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Before you decide, compare Retatrutide with Semaglutide, Liraglutide, Tirzepatide. See all →
Retatrutide is an investigational compound in the glp-1 & incretin receptor agonists.
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
It draws interest for glp-1 & incretin receptor agonists.
B-tier evidence: some human evidence exists but isn't definitive.
An investigational triple agonist (GIP/GLP-1/glucagon). A phase-2 randomized trial reported large weight reductions, but it is not approved and lacks the long-term phase-3 safety record of semaglutide and tirzepatide. Promising early human data, still investigational.
Verified citations resolve to PubMed / FDA. See how we score.
Retatrutide: the research file
What it is
Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease. It is a single synthetic peptide engineered to act as a "triple G" agonist, simultaneously stimulating three nutrient-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from the single agonist semaglutide (GLP-1) and the dual agonist tirzepatide (GIP/GLP-1), both already approved.
How it works
Retatrutide is a balanced agonist at three receptors, each contributing a distinct metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite and food intake. GIP receptor agonism further modulates insulin response and appears to improve nutrient handling and tolerability. The defining addition is glucagon receptor agonism, which raises hepatic glucose output and, importantly, increases energy expenditure and promotes hepatic lipid oxidation/mobilization. The combination is intended to layer glucagon-driven increases in energy expenditure and reductions in liver fat on top of the appetite suppression and glycemic benefits of incretin (GLP-1/GIP) signaling. Because glucagon agonism can raise hepatic glucose production and resting heart rate, the receptor balance and dose are designed to keep net effects metabolically favorable.
What the evidence shows
Human evidence comes from a completed Phase 2 program and emerging Phase 3 data, so this is no longer animal-only, though long-term outcome and safety data remain immature. In the 48-week Phase 2 obesity trial (Jastreboff et al., NEJM 2023), adults with obesity/overweight without diabetes had least-squares mean weight reductions of roughly -17.1%, -22.8%, and -24.2% across higher dose groups versus -2.1% with placebo. A parallel Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) showed substantial reductions in HbA1c and body weight. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) reported large relative reductions in liver fat, with the majority of higher-dose participants reaching liver fat below the steatosis threshold. In May 2026 Lilly reported topline Phase 3 results (TRIUMPH-1, ~2,339 adults), with the highest dose producing about 28.3% mean weight loss at 80 weeks; full peer-reviewed Phase 3 publications and the broader TRIUMPH cardiovascular/diabetes outcome trials were still pending at that time.
Safety considerations
In trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related, mostly mild to moderate, and concentrated during dose escalation; using a lower starting dose partially mitigated them. A mechanistically important signal is a dose-dependent increase in heart rate, which in the Phase 2 obesity trial peaked around 24 weeks before declining; glucagon receptor agonism also raises hepatic glucose output, requiring monitoring. Phase 3 topline data showed dose-dependent discontinuation due to adverse events. Because retatrutide is investigational, its long-term safety, cardiovascular outcomes, and effects in broad real-world populations are not yet established. Compounded, "research-use-only," or gray-market retatrutide is not quality-controlled and carries additional, unquantified risks.
Regulatory status
As of mid-2026 retatrutide is investigational and not approved by the FDA, EMA, MHRA, or any other regulator for any indication; it remains in Phase 3 development (the TRIUMPH program) by Eli Lilly. It is not a dietary supplement and any product sold as "research-use-only" retatrutide is unapproved.
- Development code LY3437943; an investigational once-weekly injectable peptide from Eli Lilly
- Single peptide acting as a triple agonist at GLP-1, GIP, and glucagon receptors
- Differs from semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1) by adding glucagon receptor agonism
- Glucagon component is thought to add increased energy expenditure and reduced liver fat
- Phase 2 obesity trial showed up to ~24% mean weight loss at 48 weeks; Phase 3 TRIUMPH-1 topline reported ~28% at 80 weeks
- Not approved anywhere as of 2026; still in Phase 3 trials
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (Jastreboff et al.) — New England Journal of Medicine, 2023, PMID 37366315
- [2]Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised phase 2 trial (Rosenstock et al.) — Lancet, 2023, PMID 37385280
- [3]Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nature Medicine, 2024, PMC11271400
- [4]Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline) — Eli Lilly / PR Newswire, 2026
Currently sits at Clinical trials — Studied in human clinical trials; evidence is meaningful.
Jargon, decoded: · · ·
Areas this compound is studied or discussed for — not guaranteed effects.
- Retatrutide is a triple agonist — it activates the GLP-1, GIP, and glucagon receptors at once.
- It is investigational (Eli Lilly), not FDA-approved; mid-stage trials have reported very large weight-loss signals among the strongest seen for an injectable.
- Adding glucagon-receptor activity is the mechanistic difference from dual agonists like tirzepatide — it may further affect energy expenditure and liver fat.
- Investigational only — efficacy and safety are still being established in trials; not approved for use.
- Long-term outcomes and tolerability versus approved agents are not yet settled.
Marketing claim vs what the data actually shows. Tap a row for detail.
Verdicts describe the state of the evidence, not invented study results. Open References for the underlying citations.
Stack fit
Decision clarity: MediumPromising evidence, but with gaps in human data, safety, or approval.
Stack verdict: Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Retatrutide is not established for:
Tier ranking
A weighted evidence score of 68/100 places retatrutide in B tier — based on published evidence, not popularity.
Weighted evidence score 68/100
Why not A: held back by regulatory clarity.
Why not C: supported by human evidence, preclinical depth, mechanism confidence, practical relevance.
What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.
What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.
- Retatrutide is not FDA-approved for human use; it is discussed in a research context.
- It belongs to the GLP-1 & incretin receptor agonists class.
- Its principal mechanism is characterized in the literature.
- Whether observed effects reliably translate to humans at large.
- Long-term safety in healthy users, and full drug-interaction risk.
- Optimal studied parameters outside any approved indication.
- Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
- Quality and purity of material from non-pharmaceutical sources.
This is not medical advice. These are areas where professional guidance and better evidence matter most.
See it next to its closest alternatives.
Full brief
A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.
- What it is
- The GLP-1 receptor agonism mechanism
- The preclinical evidence lane
- Why Emerging, and not higher or lower
- Proven lane vs speculative lane
- What people report
- Regulatory status
- What changed recently
01What it is
Simple takeaway: Retatrutide is a research compound in the glp-1 & incretin receptor agonists.
Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists. It is not approved for human use; it is discussed here in a research context only.
02The GLP-1 receptor agonism mechanism
Simple takeaway: Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
GLP-1 receptor agonists mimic the incretin hormone GLP-1. Activation increases glucose-dependent insulin secretion (so insulin rises mainly when glucose is high), slows the rate at which the stomach empties, and acts on central pathways that reduce appetite. This combination underpins their use in glucose control and weight management.
03The preclinical evidence lane
Simple takeaway: Support is mainly preclinical; 0 registered trials and 0 sources indexed.
The most defensible evidence comes from animal and mechanistic models. Human clinical evidence is present but limited.
04Why Emerging, and not higher or lower
Simple takeaway: Composite maturity 3.5/5.
What holds it back: regulatory clarity. What supports its placement: human evidence, preclinical depth, mechanism confidence, practical relevance. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.
05Proven lane vs speculative lane
Simple takeaway: The research interest is real; most popular claims remain speculative.
What's supported is the preclinical/mechanistic research. What's speculative is the broad human benefit frequently claimed online, which the indexed human evidence does not establish.
06What people report
Simple takeaway: Community reports are not clinical evidence.
Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.
07Regulatory status
Simple takeaway: Investigational
In clinical trials; not approved. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.
08What changed recently
Simple takeaway: No major evidence-changing update was identified in this review window.
The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.
How the community sees this vs the evidence.
Evidence tier is B. Do you agree?
Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.
Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.
Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.
FAQs
Is Retatrutide FDA-approved?
No. Retatrutide is not FDA-approved for the uses commonly discussed online. In clinical trials; not approved.
What is Retatrutide studied for?
Retatrutide is studied mainly for weight loss. Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists.
What does the research say about Retatrutide?
Strong human evidence. Supported by randomized or controlled human trials.
Is Retatrutide safe?
Long-term human safety is not well established for Retatrutide. Quality and purity from non-pharmaceutical sources is an added risk.
🧮 Reconstitution calculator (educational)
Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →
Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.
Show the math
More water → lower concentration → more units for the same amount.
Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.